Biologic Classification of Hodgkin Lymphoma: A New Era for an Old Disease?

Next-generation sequencing of circulating tumor DNA revealed clinically relevant subtypes and a tool to monitor minimal residual disease.

For over 50 years, the management of Hodgkin lymphoma (HL) has been based on stage at presentation and more recently by initial treatment response on interim PET scan; unlike with other lymphomas, histomorphology has not guided therapy, except for nodular lymphocyte-predominant HL. Investigators report a retrospective analysis of circulating plasma tumor DNA sequencing, gene expression profiling, and tumor microenvironment (TME) profiling in blood and tissue samples from patients enrolled in trials for previously untreated advanced-stage HL (German Hodgkin Study Group HL21) and early-stage unfavorable HL (NIVAHL). Samples and patient outcomes from a frontline pediatric HL trial (EuroNet-PHL-C2) served as the validation cohort. Minimal resid…

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Biologic Classification of Hodgkin Lymphoma: A New Era for an Old Disease?

Topics

Reviewing Author